+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis



All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis



Rheumatology International 26(9): 810-817



To study the effects of all-trans-retinoic acid (ATRA), we determined the proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) and CD4+ T cells in healthy volunteers and patients with rheumatoid arthritis (RA), and explored the possibility of using ATRA as a therapeutic agent for autoimmune diseases. Proliferation of these cells was determined by modified MTT assay, and expression of CC chemokine receptors 4 (CCR4) and CCR5 was determined by flow cytometry. Production and expression of interferon (IFN)-gamma, interleukin (IL)-2, IL-4, and tumor necrosis factor (TNF)-alpha was determined by Enzyme-Linked Immunosorbent Assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR). The presence of STAT6 protein was determined by Western blot analysis. ATRA did not affect the proliferation or production of IL-2 and IL-4. We did not detect STAT6 protein, and saw no evidence of the differentiation of PBMCs to Th1 or Th2 cells. In contrast, ATRA suppressed the production of IFN-gamma and TNF-alpha significantly. There were no significant differences between the healthy volunteers and RA patients. ATRA was demonstrated to affect the cytokine production of IFN-gamma and TNF-alpha. ATRA might be useful in the treatment of autoimmune diseases such as RA.

(PDF emailed within 0-6 h: $19.90)

Accession: 048207968

Download citation: RISBibTeXText

PMID: 16292516

DOI: 10.1007/s00296-005-0076-1


Related references

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis and Rheumatism 56(1): 13-20, 2006

Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results). Terapevticheskii Arkhiv 73(5): 12-15, 2001

Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. Journal of Clinical Investigation 86(6): 1790-1798, 1990

Production of tumor necrosis factor alpha interferon gamma and interleukin 2 by peripheral blood mononuclear cells of subjects suffering from rheumatoid arthritis. Scandinavian Journal of Rheumatology 17(3): 203-212, 1988

Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon gamma and tumor necrosis factor alpha with the characteristics of peripheral blood mononuclear cells. Rheumatology International 15(1): 31-37, 1995

Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. Cytokine 3(3): 266-267, 1991

Treating rheumatoid arthritis with anti-interferon-gamma and anti-tumor necrosis factor-alpha in a randomized, controlled trial. European Cytokine Network 14(Supplement 3): 21, Sept, 2003

Successful, first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alpha to treat rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet's syndrome). International Journal of Immunotherapy 14(1): 23-32, 1998

Activation and differentiation of myelomonocytic cells in rheumatoid arthritis and healthy individuals evidence for antagonistic in vitro regulation by interferon gamma and tumor necrosis factor alpha granulocyte monocyte colony stimulating factor and interleukin 1. Journal of Rheumatology 19(7): 1038-1044, 1992

Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. Journal of Rheumatology 37(8): 1596-1606, 2010

Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis and Rheumatism 58(5): 1258-1263, 2008

Therapeutic efficacy of tumor necrosis factor alpha tnf alpha and interferon gamma ifn gamma for friend virus erythroleukemia. Proceedings of the American Association for Cancer Research Annual Meeting 29: 431, 1988

Binding of 9-cis-retinoic acid and all-trans-retinoic acid to retinoic acid receptors alpha, beta, and gamma. Retinoic acid receptor gamma binds all-trans-retinoic acid preferentially over 9-cis-retinoic acid. Journal of Biological Chemistry 269(24): 16689-16695, 1994

Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis and Rheumatism 54(7): 2335-2337, 2006

Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cellular Immunology 156(2): 448-457, 1994